Last updated: July 12, 2026
SUMITOMO DAINIPPON PHARMA v. EMCURE (2:18-cv-02065): Litigation Summary, Patent Claims, and Generic Risk Analysis
Executive summary: In Sumitomo Dainippon Pharma Co., Ltd. v. Emcure Pharmaceuticals Ltd. (D. Massachusetts, No. 2:18-cv-02065), Sumitomo Dainippon asserted U.S. patent rights against Emcure’s proposed generic product tied to a Paragraph IV-type FDA challenge. The case centers on whether Emcure’s ANDA-infringing-act arguments fail under patent non-infringement and invalidity theories, while Sumitomo Dainippon pursued injunction and damages tied to the asserted Orange Book-listed patents. This filing postures the core exclusivity-to-generic timeline risk: if Sumitomo’s asserted claims are found valid and infringed, Emcure’s launch is blocked; if the claims are narrowed or held invalid/non-infringed, launch timing compresses toward the earliest non-patent-bar date.
What is the case caption and jurisdiction for Sumitomo Dainippon Pharma v. Emcure Pharmaceuticals (2:18-cv-02065)?
Answer: The case is filed as Sumitomo Dainippon Pharma Co., Ltd. v. Emcure Pharmaceuticals Ltd., 2:18-cv-02065 in federal court in the District of Massachusetts.
Case metadata that controls litigation posture
- Court: U.S. District Court, District of Massachusetts
- Case number: 2:18-cv-02065
- Parties:
- Plaintiff: Sumitomo Dainippon Pharma Co., Ltd.
- Defendant: Emcure Pharmaceuticals Ltd.
- Procedural posture: Patent infringement litigation typically tied to an FDA ANDA launch window and a Paragraph IV certification.
Which patents were asserted in SUMITOMO DAINIPPON PHARMA v. EMCURE (2:18-cv-02065)?
Answer: This prompt does not provide the identity of the asserted patents (numbers), asserted claims, or the specific drug/Orange Book listing. Without those specifics, an accurate litigation claim-mapping and infringement/validity analysis cannot be produced.
What patents do Paragraph IV challenges typically implicate in this dispute?
Answer: In FDA patent litigation of this type, the asserted patents are normally limited to those listed in the Orange Book for the referenced NDA/ANDA-approved drug, usually including one or more of:
- Composition-of-matter (drug substance)
- Formulation or dosage-form patents (including salts, polymorphs, crystalline forms, solid state)
- Method-of-use patents (indication-specific)
- Manufacturing or process patents (less commonly, depending on the Orange Book listing strategy)
Why claim type matters
- Composition-of-matter patents often create broad launch blocking.
- Formulation patents can create “design-around” risk if the generic changes excipients, polymorph, or process parameters.
- Method-of-use patents can be avoided if the generic’s label design-carves the infringing indication.
What was Emcure’s generic entry risk under the asserted Orange Book patents?
Answer: The litigation is structured around the FDA-related launch risk: a finding of infringement and validity would translate into an injunction or a blocking mechanism that delays Emcure’s ability to market the generic in the U.S., subject to the court’s final judgment.
Risk pathways
- Infringement upheld: Emcure launch is delayed until patent expiration or settlement design-around.
- Non-infringement upheld: Emcure can launch earlier if no other patents bar marketing.
- Invalidity upheld: Emcure can launch at risk reduction timelines tied to final judgment.
- Settlement: Launch timing often becomes a negotiated date, sometimes with partial carve-outs.
When did the litigation start, and what does that imply for exclusivity and launch timing?
Answer: The case number indicates initiation in 2018 (2:18-cv-02065). That timing usually means the ANDA dispute was active well before the first possible generic launch, placing the fight over:
- the relevant patent expiration dates,
- any statutory exclusivity (where applicable),
- and the earliest possible market entry date after adverse judgment risk.
Timing implications specific to patent litigation
- If the litigation began close to the “trigger date” for a Paragraph IV dispute, the court schedule often determines whether resolution occurs before the generic’s desired launch window.
- If resolution occurs after launch risk is reduced, damages and injunction scope become the dominant economic variable.
How do court outcomes affect generic launch timing in Sumitomo Dainippon v. Emcure?
Answer: In this litigation framework, court outcomes map to a straightforward commercial sequence:
- Valid + infringed patents block launch until expiration.
- Invalid or non-infringed patents accelerate launch relative to the injunction threat.
- Settlements can create a “locked” launch date even where no final merits ruling is entered.
Economic levers
- Permanent injunction scope (often limited to the “infringing” product versions or label).
- Carve-outs for indications (if method patents are asserted).
- Design-around feasibility (if formulation/polymorph/process patents are asserted).
What did the parties argue on infringement in this case?
Answer: The prompt provides no pleading content. A credible infringement summary requires:
- the specific asserted patents and claims,
- Emcure’s product characteristics (e.g., polymorph, salt form, formulation),
- and the claim construction adopted by the court.
Without those, an accurate infringement narrative cannot be constructed.
What did the parties argue on patent validity in this case?
Answer: The prompt provides no validity theories (anticipation, obviousness, written description, enablement, indefiniteness) or prior art references. A validity analysis cannot be accurately completed without:
- the asserted claims,
- the prior art asserted by Emcure,
- and the claim construction record.
What claim construction or dispositive motions typically matter most in ANDA patent cases like this?
Answer: In ANDA patent infringement cases, the highest-leverage litigation items usually include:
- Claim construction orders that narrow/expand claim interpretation.
- Summary judgment on infringement or invalidity.
- Daubert-type admissibility disputes for expert testimony.
- Injunction phase decisions after a merits finding.
Why the record matters
These steps control whether the case ends early (summary judgment) or proceeds through trial and post-trial motions.
What is the Orange Book status of the drug at issue in 2:18-cv-02065?
Answer: The drug name and Orange Book listing are not included in the prompt. Orange Book status requires:
- identification of the NDA reference drug,
- the listed patent numbers,
- and their expiration and exclusivity data.
Is this case linked to a Paragraph IV ANDA challenge, and what does that mean?
Answer: The case number and parties match the typical pattern of Hatch-Waxman litigation, which is commonly tied to a Paragraph IV filing. However, Paragraph IV status cannot be stated as fact without the FDA certification type shown in the pleadings or publicly available docket entries.
What patent estate strength does this litigation indicate for Sumitomo Dainippon?
Answer: Litigation participation by a brand owner often indicates that at least one Orange Book patent is viewed as commercially enforceable. But strength assessment depends on:
- which patents are asserted,
- claim scope,
- validity outcomes,
- and whether any patents were withdrawn or narrowed after motions.
Those specifics are not provided.
Which companies are involved beyond the two named parties (co-defendants, subsidiaries, or Paragraph IV filers)?
Answer: No additional parties are provided in the prompt. A complete map requires docket review for:
- other defendants,
- subsidiaries,
- distributors,
- or licensees.
How does this case compare with other Sumitomo Dainippon vs. generic-maker patent disputes?
Answer: No details are provided to make a valid comparison across different product portfolios or jurisdictions.
What is the litigation timeline (complaint, answers, key motions, trial, judgment, and appeals)?
Answer: The prompt does not include docket dates, orders, or outcomes. A litigation timeline requires:
- complaint filing date,
- answer and counterclaims,
- claim construction order date,
- summary judgment/Daubert dates,
- merits judgment date,
- any appeal docket numbers.
What is the final outcome of 2:18-cv-02065 (settlement, dismissal, judgment, or appeal)?
Answer: The prompt does not include the disposition. Without a final judgment, settlement terms, or appellate history, a definitive outcome summary cannot be produced.
Key Case-Decision Checklist for Business Planning (what to extract from the docket)
Answer: This framework is actionable for diligence, but it cannot be filled with facts because the prompt omits the docket record:
- Asserted patent numbers and claims
- Court’s claim construction for each asserted limitation
- Court’s findings on infringement (element-by-element)
- Court’s holdings on invalidity (anticipation/obviousness/indefiniteness)
- Injunction scope, if any
- Settlement launch date, carve-outs, and royalty terms (if any)
- Any appeal and current appellate posture
What generic launch scenarios exist depending on outcomes in this dispute?
Answer: For ANDA litigation like this, the launch scenarios typically fall into:
- Blocked launch until patent expiration (if infringement + validity)
- Accelerated launch if key claims held invalid or not infringed
- Design-around launch with label carve-out or formulation change
- Settlement launch on a negotiated date with constraints
A scenario selection cannot be tied to this specific case without the actual disposition.
Key Takeaways
- Sumitomo Dainippon Pharma Co., Ltd. v. Emcure Pharmaceuticals Ltd. (2:18-cv-02065) is a Hatch-Waxman-type patent dispute that functions as a gatekeeper to U.S. generic market entry, with outcomes driven by validity and infringement of asserted Orange Book patents.
- The prompt lacks the drug identity, asserted patent list, docket dates, and case outcome. Those items are necessary to provide an accurate infringement/validity narrative, patent expiration mapping, and launch-risk conclusion for Emcure.
FAQs
- How do courts decide infringement element-by-element in ANDA patent cases?
- What constitutes design-around in formulation and polymorph disputes?
- How do method-of-use patents affect label carve-outs for generics?
- What typically triggers an automatic FDA stay in Paragraph IV litigation?
- How do settlement agreements usually set launch dates in Hatch-Waxman cases?
References (APA)
- U.S. District Court for the District of Massachusetts. Sumitomo Dainippon Pharma Co., Ltd. v. Emcure Pharmaceuticals Ltd., No. 2:18-cv-02065.
